Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Guy

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Transactions of the Royal Society of Tropical Medicine and Hygiene|May 26, 2018
Dengue seroprevalence: data from the clinical development of a tetravalent dengue vaccine in 14 countries (2005-2014)Maïna L'Azou, Jade Assoukpa, Karen Fanouillere, et al.
Open Forum Infectious Diseases|January 1, 2016
Influence of FcγRIIa-Expressing Cells on the Assessment of Neutralizing and Enhancing Serum Antibodies Elicited by a Live-Attenuated Tetravalent Dengue VaccineAnthony M Byers, Ryan Broder, Kelly Haupfear, et al.
Vaccine|May 25, 2019
Complementary use of mass spectrometry and cryo-electron microscopy to assess the maturity of live attenuated dengue vaccine virusesMathieu Trauchessec, Olivier Lambert, Pierre Bonnafous, et al.
Vaccine|September 3, 2008
Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjectsBruno Guy, Nolwenn Nougarede, Sarah Begue, et al.
The American Journal of Tropical Medicine and Hygiene|February 5, 2009
Evaluation of interferences between dengue vaccine serotypes in a monkey modelBruno Guy, Veronique Barban, Nathalie Mantel, et al.
Vaccine|December 3, 2014
Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessmentThomas P Monath, Stephen J Seligman, James S Robertson, et al.
Plos Pathogens|October 3, 2013
Cross-serotype immunity induced by immunization with a conserved rhinovirus capsid proteinNicholas Glanville, Gary R McLean, Bruno Guy, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 22, 2018
Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trialsMichal Juraska, Craig A Magaret, Jason Shao, et al.
Human Vaccines & Immunotherapeutics|July 11, 2013
Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in SingaporeAnke Harenberg, Sarah Begue, Audrey Mamessier, et al.
Nature Medicine|February 5, 2008
Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammationNathan W Bartlett, Ross P Walton, Michael R Edwards, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Transactions of the Royal Society of Tropical Medicine and Hygiene|May 26, 2018
Dengue seroprevalence: data from the clinical development of a tetravalent dengue vaccine in 14 countries (2005-2014)Maïna L'Azou, Jade Assoukpa, Karen Fanouillere, et al.
Open Forum Infectious Diseases|January 1, 2016
Influence of FcγRIIa-Expressing Cells on the Assessment of Neutralizing and Enhancing Serum Antibodies Elicited by a Live-Attenuated Tetravalent Dengue VaccineAnthony M Byers, Ryan Broder, Kelly Haupfear, et al.
Vaccine|May 25, 2019
Complementary use of mass spectrometry and cryo-electron microscopy to assess the maturity of live attenuated dengue vaccine virusesMathieu Trauchessec, Olivier Lambert, Pierre Bonnafous, et al.
Vaccine|September 3, 2008
Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjectsBruno Guy, Nolwenn Nougarede, Sarah Begue, et al.
The American Journal of Tropical Medicine and Hygiene|February 5, 2009
Evaluation of interferences between dengue vaccine serotypes in a monkey modelBruno Guy, Veronique Barban, Nathalie Mantel, et al.
Vaccine|December 3, 2014
Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessmentThomas P Monath, Stephen J Seligman, James S Robertson, et al.
Plos Pathogens|October 3, 2013
Cross-serotype immunity induced by immunization with a conserved rhinovirus capsid proteinNicholas Glanville, Gary R McLean, Bruno Guy, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 22, 2018
Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trialsMichal Juraska, Craig A Magaret, Jason Shao, et al.
Human Vaccines & Immunotherapeutics|July 11, 2013
Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in SingaporeAnke Harenberg, Sarah Begue, Audrey Mamessier, et al.
Nature Medicine|February 5, 2008
Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammationNathan W Bartlett, Ross P Walton, Michael R Edwards, et al.
Pageof 6